Header cover image

Swedish (OMX) Life Sciences Industry Analysis

UpdatedJan 24, 2022
DataAggregated Company Financials
  • 7D-3.5%
  • 3M-32.9%
  • 1Y30.0%
  • YTD-23.3%

Over the last 7 days, the Life Sciences industry has dropped 3.5%, driven by a pullback from AddLife of 6.5%. Meanwhile, BICO Group actually outperformed within the industry, gaining 5.9% in the last week. This takes the industry's 12 month performance to a gain of 30%.

Industry Valuation and Performance

Has the Swedish Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Mon, 24 Jan 2022kr66.8bkr10.8bkr786.3m44.8x
Wed, 22 Dec 2021kr82.0bkr10.8bkr786.3m54.9x
Fri, 19 Nov 2021kr89.2bkr10.8bkr788.5m55.6x
Sun, 17 Oct 2021kr93.3bkr9.9bkr853.6m54.6x
Tue, 14 Sep 2021kr101.3bkr9.9bkr853.6m58.6x
Thu, 12 Aug 2021kr90.9bkr9.9bkr853.6m47.9x
Mon, 07 Jun 2021kr74.6bkr8.5bkr852.0m46.2x
Sun, 28 Feb 2021kr55.1bkr7.7bkr693.0m51.6x
Wed, 02 Dec 2020kr39.8bkr6.7bkr455.0m42.2x
Sat, 05 Sep 2020kr41.2bkr6.3bkr389.2m63.8x
Tue, 09 Jun 2020kr30.5bkr5.9bkr322.2m62.1x
Mon, 02 Mar 2020kr24.6bkr5.6bkr326.8m52.7x
Thu, 05 Dec 2019kr22.6bkr5.2bkr342.9m50.6x
Sun, 08 Sep 2019kr20.4bkr4.9bkr317.5m59.5x
Sat, 01 Jun 2019kr19.4bkr4.6bkr299.9m50x
Tue, 05 Mar 2019kr18.9bkr4.3bkr274.8m47.9x
PE Ratio


Total Market Cap: kr16.7bTotal Earnings: kr273.6mTotal Revenue: kr4.2b0%0%0%3 Year10 Year

Current Industry PE: Investors are relatively neutral on the industry at the moment, considering it's trading close to its 3-year average PE ratio of 51.9x. It appears they believe that earnings will grow in-line with historical growth rates.

Past Earnings Growth: The earnings for companies in the Life Sciences industry have grown 42% per year over the last three years, and revenues for these companies have grown 37% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Life Sciences industry?

Clinical Research and Equipment-3.51%

Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 51.9x. However analysts are expecting annual earnings growth of 67%, which is lower than the prior year's growth of 78% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 67% over the next 5 years. This is roughly in line with its past earnings growth rate.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BICO BICO Groupkr222.405.9%
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News